In newly diagnosed patients with AML unfit for intensive chemotherapy (phase 3 AGILE study), ivosidenib and AZA resulted in higher rates of IDH1-MRDneg as compared with ivosidenib and a placebo (17/33 [51.5%] vs. 3/10 [30.0%]) [87]. This evidence concerns the gene IDH1 and acute myeloid leukemia.